Imaging and biomarker factors for predicting durable responses to 177Lu-PSMA therapy in metastatic castration resistant prostate cancer (mCRPC).

Authors: Alin Chirindel, Guillaume Nicolas, Abdel B. Halim, Mark S. Kidd

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17070

Source: Full article

---

Abstract

e17070